6CM
ORMP icon

683 Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

683 Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,537
Closed -$247K – 321
2022
Q4 		$247K Buy
+20,537
New +$160K 0.02% 141

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

683 Capital Management's ORMP Position: Q1 2023 in Review

683 Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 20,537 shares — an estimated $247K sold.

683 Capital Management first reported a position in ORMP in Q4 2022 and held it in 1 quarter. The position peaked at $247K in Q4 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • 683 Capital Management reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • 683 Capital Management sold 20,537 Oramed Pharmaceuticals shares in Q1 2023, an estimated $247K.
  • 683 Capital Management first reported a position in Oramed Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • 683 Capital Management's Oramed Pharmaceuticals position peaked at $247K in Q4 2022.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.